Novo Nordisk A/S v KBP Biosciences Pte. Ltd. & Anor

[2025] SGHC(I) 3 Singapore International Commercial Court 14 February 2025 • SIC/OA 3/2025 ( SIC/SUM 11/2025 ) • 7 min read

2 cases cited (1 SG, 1 foreign)

Catchwords

Civil Procedure — Mareva injunctions — Claimant making ex parte application for worldwide Mareva injunction in support of New York-seated arbitration –– Whether appropriate to grant worldwide Mareva injunction – Section 12A International Arbitration Act 1994

Practice Areas

Civil Procedure

Judges (1)

Philip Jeyaretnam Delivered

Counsel (4)

Setia Law LLC Firm Ong Tun Wei Danny Counsel Claimant Teo Jason Counsel Claimant Zhang Haowei Elvis Counsel Claimant

Parties (3)

KBP Biosciences Pte. Ltd. Defendant Novo Nordisk A/S Claimant Huang Zhenhua Defendant

Summary

Novo Nordisk obtained an ex parte worldwide freezing order against KBP Biosciences and its founder Dr Huang Zhenhua in support of a planned New York-seated ICC arbitration claiming US$830 million in damages for alleged fraud in the acquisition of the drug Ocedurenone. The SICC granted the injunction under s 12A of the International Arbitration Act, finding a good arguable case of fraud, a real risk of dissipation, and that no arbitral tribunal had yet been constituted to address the matter.

Statutes Cited

Arbitration Act (Cap 10)

International Arbitration Act (Cap 143A)

s 12A(2)

Supreme Court of Judicature Act (Cap 322)

s 18I

Cases Cited (2)

SLR (1)

[2015] 5 SLR 558

UK (1)

[2003] EWCA Civ 752

Judgment

Read the full judgment on the official Singapore Courts portal.

Read on eLitigation

Source: eLitigation ([2025] SGHC(I) 3)